



BA-BCS 2024 PROGRAM

TUESDAY, SEPTEMBER 3

Welcome and Opening Keynote Lecture

17:00-18:00 Registration

18:00-18:30 Welcome

18:30-19:30 Opening Conference

Robert Clarke, University of Manchester, Manchester, UK.

The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis.

WEDNESDAY, SEPTEMBER 4

Session 1: Luminal breast cancer

9:30-11:15

9:30-10:00 Carol Lange, University of Minnesota, Minneapolis, USA.

Policing Nuclear Receptor Playmates: Tracking ER/PR Complexes in Luminal Breast Cancer.

10:00-10:30 Todd Miller, Medical College of Wisconsin Cancer Center, Milwaukee, USA.

Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.

10:30-11:00 Joseph Jerry, University of Massachusetts, Amherst, USA.

A panel of normal breast epithelial cells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.

11:00-11:15 **Discussion**

Coffee Break

11:15-11:30

Session 2: Luminal breast cancer 2

11:30-13:15

11:30-12:00 Stephen Birrell, The Breast and Endocrine Center, Adelaide, Australia.

After 130 years of hormonal therapy in breast cancer-are we going the wrong way?

12:00-12:30 Jennifer Richer, University of Colorado, Aurora, USA.

A new look at breast cancers resistant to traditional endocrine therapy.

12:30-12:45 Short communication to be selected from poster presentations

12:45-13:00 Federico Waisberg, Instituto Fleming, Buenos Aires

New treatments and biomarkers in hormone resistant (HR+) breast cancer.

13:00-13:15 **Discussion**

Lunch and Poster Session 1

13:15-14:45

Session 3: Biology and treatment of TNBC

14:45-16:30

14:45-15:15 Violeta Serra, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
PARP inhibition in breast cancer.

15:15-15:45 Paolo Ceppi, University of Southern Denmark, Odense, Denmark.
Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?

15:45-16:00 Short communication to be selected from poster presentations.

16:00-16:15 Pablo Mandó, CEMIC, Buenos Aires
New therapeutic options for TNBC.

16:15-16:30 **Discussion**

Break and poster discussions Session 1

16:30-17:30

Round Table 1 (Spanish)

17:30-19.00

Utilidad clínica de la búsqueda de marcadores circulantes en biopsia líquida, para el redireccionamiento y/o seguimiento de la carga tumoral en pacientes con cáncer de mama.

THURSDAY, SEPTEMBER 5

Session 4: Cancer Stem Cells and Tumor Initiation

9:30-11:15

9:30-10:00 Fariba Behbod, University of Kansas, Kansas City, USA.
Ductal carcinoma in situ: Transcriptional diversity and stemness.

10:00-10:30 Jochen Maurer, University Hospital RWTH, Aachen, Germany.
Cancer stem cells as disease models in research – opportunities and challenges.

10:30-11:00 William Muller, Rosalind and Morris Goodman Cancer Center, Montreal, Canada.
Title to be determined.

11:00-11:15 **Discussion**

Coffee Break

11:15-11:30

Session 5: Breast Cancer Genomics and Transcriptomics

11:30-13:15

- 11:30-12:00 Martin Abba, UNLP, La Plata, Argentina
Old questions, new tools
- 12:00-12:30 Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York City, USA.
Breast cancer genomics and resistance to CDK4/6i or on MSK Breast Molecular Tumor Board.
- 12:30-12:45 Short communication to be selected from poster presentations
- 12:45-13:00 Gonzalo Gomez Abuin, Hospital Alemán, Buenos Aires
Utility of next generation sequencing in breast cancer
- 13:00-13:15 **Discussion**

Lunch and Posters Session 2

13:15-15:15

Session 6: Fighting treatment resistance

15:15-17:00

-

- 15:15-15:45 Adrian Lee, University of Pittsburgh, Pittsburgh, USA.
Endocrine resistance in breast cancer metastasis.
- 15:45-16:15 Dejan Juuric, Massachusetts General Hospital, Boston, USA.
Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors
- 16:15-16:30 Short communication to be selected from poster presentations
- 16:30-16:45 **Oncologist to be determined**
Managing treatment resistance at the public hospital.
- 16:45-17:00 **Discussion**

Coffee Break and poster discussions

17:00-17:30

Round Table 2 (Spanish)

17:30-19.00

Jerarquización en investigación dentro de la carrera de formación de los médicos, experiencias en CEMIC, Fleming y Austral.

FRIDAY SEPTEMBER 5

Session 7: Early detection and treatment

9:30-11:15

9:30-10:00 Roger Chammas, Center for Translational Research in Oncology, University of São Paulo, Brazil.
miRNAs as biomarkers for early onset Triple Negative Breast Cancers.

10:00-10:30 Cathrine Park, University of California, San Francisco, USA.
Evolution of breast radiotherapy options for today's early stage patients.

10:30-10:45 Short communication to be selected from poster presentations.

10:45-11:00 Adriana de Siervi, Oncoliq, Buenos Aires.
miRNAs for early cancer detection in liquid biopsy.

11:00-11:15 **Discussion**

Coffee Break

11:15-11:30

Session 8: Understanding and modeling breast cancer subtypes

11:30-13:30

11:30-12:00 Steffi Oestereich, University of Pittsburgh, Pittsburgh, USA.
Invasive lobular breast cancer – what's different and why is this important?

12:00-12:30 Alana Welm, The University of Utah, Salt Lake City, Utah.
Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer

12:30-13:00 Speaker to be determined

13:00-13:15 Short communication to be selected from poster presentations.

13:15-13:30 Discussion

Lunch and Posters Session 3

13:30-15:30

Closing Conference

15:30-16:30 Charles Perou. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
Quantitative Medicine for Breast Cancer Patients

Final discussions and closing remarks

16:30-16:45 Organizers

Coffee Break

16:45-17:00

Round Table 3 (Spanish)

17:00:19:00

Navegación en el sistema de salud para pacientes con bajo y alto riesgo de cáncer de mama.
Situación actual en la región Norte, Centro y Sur del país.